Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Gold, Energy, and the Future of the Global Monetary System with Luke Gromen

    Macro strategist Luke Gromen, Founder and President of Forest for the Trees, joins William Blair's Jed Dorsheimer to explore the intricate relationship between gold, energy, and the evolving global monetary order.

    Listen to the podcast

  • GENUI Has Acquired PFANNER

    William Blair acted as the exclusive financial advisor to GENUI in connection with its acquisition of PFANNER.

    Read more

  • Unattended Retail Technology and Payments

    Technology is reshaping unattended retail, enabling seamless transactions and accelerating the adoption of electronic payments.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures